MarketBeat Week in Review – 02/23 – 02/27 Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities.
On a call with analysts, Tempus said it agreed to acquire all outstanding shares of Personalis not already owned by Tempus at $16.25 per share
The company said the price represents a 6% premium to Personalis’ Friday closing price and a 28% premium to its unaffected 30-day volume-weighted average price. – After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound The consideration is structured as 100% stock, though Tempus has the option to pay up to 50% in cash. Personalis shareholders would receive a floating exchange ratio of Tempus common stock for each Personalis share held at closing, subject to a maximum exchange ratio of 0.3356. Tempus said any cash portion could be financed with cash on hand and additional borrowing procured between signing and closing.
The companies expect the transaction to close in late 2026 or early 2027. Tempus Points to MRD Growth and Reimbursement Momentum Tempus said Personalis’ NeXT Personal offering has seen strong adoption, with quarter-over-quarter growth of 38%. The company said volumes could become “even more material and higher” as additional sales representatives are equipped to sell the offering and as more indications secure reimbursement. – Tempus AI Sold Off After a Beat—But the Rebound Case Is Building In response to a question from Kallum Titchmarsh of Morgan Stanley, an executive identified as Eric said Tempus is “quickly gaining market adoption,” citing both overall growth in the MRD market and the performance of Personalis’ assay.